Effect Of Drd2/Ankk1 Taqia Allelic Polymorphism On The Risk And Prognosis Of Cervical Precancer And Cancer

József Cseh, Zsuzsa Orsós, Emese Pázsit, Erika Marek, András Huszár, István Ember, István Kiss

Abstract


Objectives: The aim of this study was to elucidate the role of dopamine receptor D2 / ankyrin repeat and protein kinase domain containing 1 (DRD2/ANKK1) TaqIA allelic polymorphism in the HPV-induced cervical carcinogenesis.

Methods: 1. Effect on the risk of cervical precancer: After an 8-year follow-up, out of 214 women with persisting high-risk HPV infection, 102 developed high-grade cervical dysplasia or cervical intraepithelial neoplasia (CIN) grade III, while 112 did not. The subjects were genotyped for the DRD2/ANKK1 TaqIA polymorphism by PCR-RFLP, and the allelic distributions were compared between groups with and without high-grade dysplasia. 2. Prognostic value: Two hundred and thirty nine women with cervical precancer/cancer were followed for 5 years. Complete remission was achieved at 182 women. To assess the prognostic value of the TaqIA polymorphism, genotype frequencies were compared between patients reaching and not reaching complete remission.

Results: The frequency of A1/A1+A1/A2 genotypes was higher among women who developed high-grade cervical dysplasia (OR: 1.87, 95% CI: 1.05-3.33; p=0.034) than in the other group. Occurrence of the A1 allele was more frequent among women who did not reach complete remission (OR: 2.00, 95% CI: 1.07-3.74; p=0.030) than in women with complete remission.

Conclusions: This is the first report on the possible involvement of DRD2/ANKK1 TaqIA polymorphism in cervical carcinogenesis. The A1 allele seems to increase the risk of cervical precancer, and it may also be associated with a worse prognosis in women with HPV-induced cervical cancer. The results need further validation in large-scale molecular epidemiological studies.


Keywords


Cervical Cancer, Precancer, DRD2, Polymorphism, HPV

Full Text:

PDF

References


Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer Journal for Clinicians 2010;60(5):277-300.

IARC. Monographs on the Evaluation of Carcinogenic Risks to Humans. Human Papillomaviruses, Vol. 64, Human Papillomaviruses. Lyon: International Agency for Research on Cancer, 1995.

Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. Journal of Clinical Pathology 2002;55:244-65.

Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006;24:S1–10.

Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. Journal of the National Cancer Institute 1995;87:796–802.

Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. New England Journal of Medicine 2003;348: 518–27.

Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. Journal of Pathology 1999;189:12–9.

Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007; 370: 890–907.

Morrison EAB, Ho GYF, Vermund SH, Goldberg GL, Kadish AS, Kelley KF and Burk RD. Human papillomavirus infection and other risk factors for cervical neoplasia: a case-control study. International Journal of Cancer 1991;49:6-13.

Waggoner SE, Darcy KM, Tian C, Lanciano R. Smoking behavior in women with locally advanced cervical carcinoma: a Gynecologic Oncology Group study. American Journal of Obstetrics and Gynecology 2010;202(3):283.e1-7.

Palma S, Novelli F, Padua L, Venuti A, Prignano G, Mariani L, Cozzi R, Tirindelli D, Testa A. Interaction between glutathione-S-transferase polymorphisms, smoking habit, and HPV infection in cervical cancer risk. Journal of Cancer Research and Clinical Oncology 2010;136(7):1101-9.

Gadducci A, Barsotti C, Cosio S, Domenici L, Riccardo Genazzani A. Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: a review of the literature. Gynecological Endocrinology 2011;27(8):597-604.

Reiche EMV, Nunes SOV, Morimoto HK. Stress, depression, the immune system, and cancer. Lancet Oncol 2004;5:617–25.

Paskett ED, McLaughlin JM, Reiter PL, Lehman AM, Rhoda DA, et al. Psychosocial predictors of adherence to risk-appropriate cervical cancer screening guidelines: a cross sectional study of women in Ohio Appalachia participating in the Community Awareness Resources and Education (CARE) project. Preventive Medicine 2010;50(1-2):74.

Schmale A, Iker H. The psychological setting of uterine cervical cancer. Annals of the New York Academy of Sciences 1966;125(3):807-13.

Chiesa A, Serretti A. A systematic review of neurobiological and clinical features of mindfulness meditations. Psychological Medicine 2010 Aug;40(8):1239-52.

Schultz W. Potential vulnerabilities of neuronal reward, risk, and decision mechanisms to addictive drugs. Neuron 2011;69(4):603-17.

Heinz A, Schlagenhauf F. Dopaminergic dysfunction in schizophrenia: salience attribution revisited. Schizophreny Bulletin 2010;36(3):472-85.

Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from structure to function. Physiological Reviews 1998;78:189–225.

Spanagel R, Weiss F. The dopamine hypothesis of reward: past and current status. Trends in Neurosciences 1999;22(11):521-7.

Callier S, Snapyan M, Le Crom S, Prou D, Vincent JD, Vernier P.: Evolution and cell biology of dopamine receptors in vertebrates. Biology of the Cell 2003;95(7):489-502.

Thompson J, Thomas N, Singleton A, Piggot M, Lloyd S, Perry EK, et al. D2 dopamine receptor gene (DRD2) Taql A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 1997;7(6):479-484.

Noble EP. D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. American Journal of Medical Genetics Part B (Neuropsychiatric Genetics) 2003;116B:103–125.

Eisenberg DT, Campbell B, Mackillop J, Lum JK, Wilson DS. Season of birth and dopamine receptor gene associations with impulsivity, sensation seeking and reproductive behaviors. PLoS One 2007;2(11):e1216.

Comings DE, Blum K. Reward deficiency syndrome: genetic aspects of behavioral disorders. Progress in Brain Research 2000;126:325-41.

Batra A, Gelfort G, Bartels M, Smoltczyk H, Buchkremer G, Riess O, Schöls L. The dopamine D2 receptor (DRD2) gene-a genetic risk factor in heavy smoking? Addiction Biology 2000;5(4):429-36.

Gorwood P, Batel P, Gouya L, Courtois F, Feingold J, Adès J. Reappraisal of the association between the DRD2 gene, alcoholism and addiction. European Psychiatry 2000;15(2):90-6.

Pato CN, Macciardi F, Pato MT, Verga M, Kennedy JL. Review of the putative association of dopamine D2 receptor and alcoholism: a meta-analysis. American Psychol Med of Medical Genetics 1993;48(2):78-82.

Campa D, Zienolddiny S, Lind H, Ryberg D, Skaug V, Canzian F, Haugen A. Polymorphisms of dopamine receptor/transporter genes and risk of non-small cell lung cancer. Lung Cancer 2007;56(1):17-23.

Gemignani F, Landi S, Moreno V, Gioia-Patricola L, Chabrier A, Guino E, et al. Polymorphisms of the dopamine receptor gene DRD2 and colorectal cancer risk. Cancer Epidemiology Biomarkers and Prevention. 2005 Jul;14(7):1633-8.

Comings DE, Gade-Andavolu R, Cone LA, Muhleman D, MacMurray JP. A multigene test for the risk of sporadic breast carcinoma. Cancer 2003;97(9):2160-70.

Ponce G, Pérez-González R, Aragüés M, Palomo T, Rodríguez-Jiménez R, Jiménez-Arriero MA, et al. The ANKK1 kinase gene and psychiatric disorders. Neurotoxicology Research 2009;16(1):50-9.

Eisenberg DT, Mackillop J, Modi M, Beauchemin J, Dang D, Lisman SA, Lum JK, Wilson DS. Examining impulsivity as an endophenotype using a behavioral approach: a DRD2 TaqI A and DRD4 48-bp VNTR association study. Behavioral and Brain Functions 2007;3:2.

Ma YT, Collins SI, Young LS, Murray PG, Woodman CBJ. Smoking initiation is followed by the early acquisition of epigenetic change in cervical epithelium: a longitudinal study. British Journal of Cancer 2011;104, 1500-1504

Schiffman M, Herrero R, Desalle R, et al. The carcinogenicity of human papillomavirus types refl ects viral evolution. Virology 2005;337: 76–84.

Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specifi c HPV testing in clinical practice. Journal of the National Cancer Institute 2005;97:1072–79.

Castle PE, Solomon D, Schiff man M, Wheeler CM. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. Journal of the National Cancer Institute 2005;97:1066–71.

Vineis P. The relationship between polymorphisms of xenobiotic metabolizing enzymes and susceptibility to cancer. Toxicology 2002;181-182:457-62.

Taskiran C, Aktas D, Yigit-Celik N, Alikasifoglu M, Yuce K, Tunçbilek E, Ayhan A. CYP1A1 gene polymorphism as a risk factor for cervical intraepithelial neoplasia and invasive cervical cancer. Gynecological Oncology 2006;101(3):503-6.

Ferreira PM, Catarino R, Pereira D, Matos A, Pinto D, Coelho A, Lopes C, Medeiros R. Cervical cancer and CYP2E1 polymorphisms: implications for molecular epidemiology. European Journal of Clinical Pharmacology 2006;62(1):15-21.

Shekari M, Sobti RC, Tamandani DM, Malekzadeh K, Kaur P, Suri V. Association of genetic polymorphism of the DNA base excision repair gene (APE-1 Asp/148 Glu) and HPV type (16/18) with the risk of cervix cancer in north Indian population. Cancer Biomarkers 2008;4(2):63-71

Niwa Y, Matsuo K, Ito H, Hirose K, Tajima K, Nakanishi T, et al. Association of XRCC1 Arg399Gln and OGG1 Ser326Cys polymorphisms with the risk of cervical cancer in Japanese subjects. Gynecological Oncology 2005 Oct;99(1):43-9.

Katiyar S, Thelma BK, Murthy NS, Hedau S, Jain N, Gopalkrishna V, Husain SA, Das BC: Polymorphism of the p53 codon 72 Arg/Pro and the risk of HPV type 16/18-associated cervical and oral cancer in India. Molecular and Cellular Biochemistry 2003;252(1-2):117-24.

Klug SJ, Wilmotte R, Santos C, Almonte M, Herrero R, Guerrero I, Caceres E, Peixoto-Guimaraes D, Lenoir G, Hainaut P, Walboomers JM, Muñoz N. TP53 polymorphism, HPV infection, and risk of cervical cancer. Cancer Epidemiology Biomarkers and Prevention 2001;10(9):1009-12.

Min-min H, Ming-rong X, Ze-yi C, Kai-xuan Y, Zhi-lin S. Analysis of p53 codon 72 polymorphism and its association with human papillomavirus 16 and 18 E6 in Chinese cervical lesions. International Journal of Gynecological Cancer 2006;16(6):2004-8.

Joe KH, Kim DJ, Park BL, Yoon S, Lee HK, Kim TS, Cheon YH, Gwon DH, Cho SN, Lee HW, Namgung S, Shin HD.: Genetic association of DRD2 polymorphisms with anxiety scores among alcohol-dependent patients. Biochemical and Biophysical Research Communications 2008;371(4):591-5.

Munafò MR, Timpson NJ, David SP, Ebrahim S, Lawlor DA. Association of the DRD2 gene Taq1A polymorphism and smoking behavior: a meta-analysis and new data. Nicotine and Tobacco Reserach 2009;11(1):64-76.

Le Foll B, Gallo A, Le Strat Y, Lu L, Gorwood P. Genetics of dopamine receptors and drug addiction: a comprehensive review. Behavioral Pharmacology 2009;20(1):1-17.

Doehring A, Kirchhof A, Lötsch J. Genetic diagnostics of functional variants of the human dopamine D2 receptor gene. Psychiatric Genetics 2009;19(5):259-68.

Esposito-Smythers C, Spirito A, Rizzo C, McGeary JE, Knopik VS. Associations of the DRD2 TaqIA polymorphism with impulsivity and substance use: preliminary results from a clinical sample of adolescents. Pharmacology Biochemistry and Behavior 2009;93(3):306-12.

Halpern CT, Kaestle CE, Guo G, Hallfors DD. Gene-environment contributions to young adult sexual partnering. Archives of Sexual Behavior 2007;36(4):543-54.

Gemignani F, Landi S, Moreno V, Gioia-Patricola L, Chabrier A, Guino E, et al. Polymorphisms of the dopamine receptor gene DRD2 and colorectal cancer risk. Cancer Epidemiology Biomarkers and Prevention 2005;14(7):1633-8.

Murphy G, Cross AJ, Sansbury LS, Bergen A, Laiyemo AO, Albert PS, Wang Z, Yu B, Lehman T, Kalidindi A, Modali R, Schatzkin A, Lanza E. Dopamine D2 receptor polymorphisms and adenoma recurrence in the Polyp Prevention Trial. International Journal of Cancer 2009;124(9):2148-51.

Chang AR. Carcinoma in situ of the cervix and its malignant potential. A lesson from New Zealand. Cytopathology 1990; 1:321–28.

Kinlen LJ, Spriggs AI. Women with positive cervical smears but without surgical intervention. A follow-up study. Lancet 1978; 2:463–65.

Hsieh YY, Chang CC, Bau DT, Tsai FJ, Tsai CH, Chen CP.The p21 codon 31*C- and DRD2 codon 313*T-related genotypes/alleles, but not XRCC1 codon 399, hOGG1 codon 326, and DRD1-48 polymorphisms, are correlated with the presence of leiomyoma. Fertility and Sterility 2009 Mar;91(3):869-77.

Sangrajrang S, Sato Y, Sakamoto H, Ohnami S, Khuhaprema T, Yoshida T. Genetic polymorphisms in folate and alcohol metabolism and breast cancer risk: a case-control study in Thai women. Breast Cancer Research and Treatment 2010 Oct;123(3):885-93.

Clague J, Cinciripini P, Blalock J, Wu X, Hudmon KS. The D2 dopamine receptor gene and nicotine dependence among bladder cancer patients and controls. Behavioral Genetics 2010 Jan;40(1):49-58.




DOI: http://dx.doi.org/10.12955/emhpj.v4i0.362

Refbacks

  • There are currently no refbacks.


Print ISSN 1804-5804, Online ISSN 1804-9702

(c) 2018 CBU,o.p.s.